Research on the use of targeted combined immunization before surgery for high-risk renal cancer to reduce the stage reduction of kidney tumors and improve the resectability rate of surgery

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072770

Enrollment

Unknown

Registered

2023-06-25

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal carcinoma

Interventions

Experimental group:Intravenous tirelizumab and oral pezopanib for 12 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age= 18 years old 2. Histopathology diagnosed as kidney cancer with vena cava cancer thrombus 3. Radical resection of renal cancer combined with inferior vena cava cancer thrombus removal according to guidelines 4. ECOG score= 1 point 5. Life expectancy of at least 3 months 6. Not accompanied by distant metastases 7. Not receiving other drugs 8. Adequate bone marrow, kidney, liver function and laboratory parameters.

Exclusion criteria

Exclusion criteria: recent treatment with other medications; recent history of cardiac or vascular events; Participated in other clinical trials in the last 3 months; have no or limited legal capacity; Pezopanib, tislelizumab contraindications, allergies, adverse reactions

Design outcomes

Primary

Measure	Time frame
Cancer thrombus degradation rate;	—

Secondary

Measure	Time frame
Disease free survival, DFS;Overall survival,OS;Adverse reaction, AR;	—

Countries

China

Contacts

Public ContactBaihetiya·Azhati

The First Affiliated Hospital of Xinjiang Medical University

bhty08@sina.cn+86 159 9912 5440

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026